Latest Biological warfare Stories
PRINCETON, N.J., May 14, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012. Soligenix's revenues for the quarter ending March 31, 2012 were $647,418 as compared to $808,005 for the first quarter of 2011. The decrease in revenues was related to a reduction in reimbursable costs from the Company's Orphan Drug Grant...
SAN DIEGO, May 1, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has exercised its option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the contract supporting the development of a robust Pf?nex Expression Technology(TM) based production strain and process for the production of bulk recombinant...
PRINCETON, N.J., April 25, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today further progress in the development of ThermoVax(TM), its proprietary vaccine thermostabilization technology. Progress has been based on additional characterization of the stability of prototype vaccines that have been kept at elevated temperatures in excess of three months. These studies are being conducted as part...
ANNAPOLIS, Md., April 12, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer, presented a comprehensive update on the Company's novel SparVax(TM) rPA anthrax vaccine program at the 2012 World Vaccine Congress, held at the Gaylord National Convention Center in Washington, DC, April 11-14, 2012. SparVax(TM) is being developed to meet the government's need for an improved second...
CHARLOTTE, N.C., March 14, 2012 /PRNewswire/ -- Chemring Detection Systems ("CDS") a Chemring Group ("Chemring") company, announced a $9M contract award to supply biological detection systems to the Japanese Ministry of Defense. The award was made by Marubeni Aerospace Corporation. The systems will be installed in the Japanese Ground Self Defense Force (JGSDF) NBC Reconnaissance Vehicle. The system is a variant of the US DOD Joint Biological Point Detection System (JBPDS) and was...
Offsite Planning to Reduce the Public's Exposure to Radiation BALTIMORE, March 7, 2012 /PRNewswire-USNewswire/ -- In a report released today, researchers at the Center for Biosecurity of UPMC assess offsite policies and plans that can be put in place to reduce the exposure of the public to radiation in the event of a nuclear power plant accident. Even amidst the devastation following the earthquake and tsunami in Japan last year that killed more than 20,000 people, it was the...
PRINCETON, N.J., Feb. 6, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGXD) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from preclinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other components that ordinarily would not withstand long temperature variations exceeding customary...
PRINCETON, N.J., Jan. 18, 2012 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today results from long-term stability studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant protective antigen) subunit protein vaccine, known as SGX204. SGX204 is a hyperimmunogenic derivative of PA and is being developed as a vaccine to protect against anthrax disease either as a...
Vaccination with the anthrax capsule—a naturally occurring component of the bacterium that causes the disease—protected monkeys from lethal anthrax infection, according to U.S. Army scientists. The study, which appears in the Jan. 20th print edition of the journal VACCINE, represents the first successful use of a non-toxin vaccine to protect monkeys from the disease. Bacillus anthracis, the bacterium that causes anthrax, is recognized as one of the most serious bioterrorism threats. It...
PRINCETON, N.J., Dec. 15, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. Initial development work will be covered...
